What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
All seven of 23andMe’s independent directors resigned on September 17, 2024—not every board member except the CEO. In their resignation letter, they said CEO Anne Wojcicki had not presented a fully financed, fully diligenced, actionable plan to take the company private that they believed served unaffiliated shareholders. They also cited a strategic disagreement and Wojcicki’s concentrated voting power. The directors did not say they were resigning “in disgust.”
What the directors said prompted their resignations
The seven independent directors said they had spent months working with Wojcicki on her effort to take 23andMe private. They wrote that she had not provided “a fully financed, fully diligenced, actionable proposal” that they considered to be in the best interests of unaffiliated shareholders. They also said there had been no notable progress over the preceding five months and that the Special Committee would not consider further extensions. The directors’ September 17, 2024 letter sets out their account of the dispute.
The directors described a broader difference over the company’s strategic direction and pointed to Wojcicki’s concentrated voting power. They wrote: “Because of that difference and because of your concentrated voting power, we believe that it is in the best interests of the Company’s shareholders that we resign from the Board rather than have a protracted and distracting difference of view with you as to the direction of the Company.” That is the directors’ explanation, not an independent finding about their private motives.
They said they preferred to resign rather than prolong a distracting disagreement, while continuing to support 23andMe’s mission and personalized-health offering. The letter stated: “We, the independent directors of the 23andMe Board, hereby tender our resignations, effective immediately.” It was signed by Roelof Botha, Patrick Chung, Sandra Hernández, M.D., Neal Mohan, Valerie Montgomery Rice, M.D., Richard Scheller, Ph.D., and Peter J. Taylor.
#1 Best Overall
- MAP YOUR ORIGINS ACROSS 5,000+ REGIONS: Ancestry Composition breaks down your ethnicity across 5,000+ geographic regions worldwide, the most detailed ancestry breakdown of any consumer DNA service. Ancestry Timeline estimates how many generations ago your most recent ancestor from each population lived.
- FIND LIVING RELATIVES: Opt in to DNA Relatives to see up to 1,500 people in the 23andMe database who share DNA with you, from close family to distant cousins, and message them directly. Your Family Tree builds itself automatically based on your DNA.
- DISCOVER WHAT MAKES YOU UNIQUE: See how your DNA may influence physical features, sensory preferences, and habits across 30+ traits, including cilantro taste aversion to hair texture to deep sleep.
- TRACE ANCIENT MIGRATIONS: Maternal and Paternal Haplogroup reports follow your ancestors' migration paths across continents over thousands of years (paternal haplogroup requires a Y chromosome). Find out how much of your ancestry can be traced back to the Neanderthals.
- PRIVATE BY DESIGN: Your DNA data is encrypted, protected, and always under your control. Enhanced security measures are implemented to keep your information safe. Subject to 23andMe’s Terms of Service and Privacy Statement at 23andMe online.
Which directors left—and which did not
The company identified the departing group as its seven independent directors. The precise description is therefore that all seven independent directors resigned, effective immediately, while Wojcicki remained on the board at that time—not that every director except the CEO left. 23andMe’s announcement lists the departing directors and the date of their resignations.
How the dispute developed after 2024
The disagreement formed part of Wojcicki’s effort to acquire the company and take it private. In March 2025, 23andMe said its Special Committee had rejected her acquisition proposal. On March 23, the company announced a voluntary Chapter 11 process. In the same announcement, it said Wojcicki was resigning as CEO by mutual agreement with the Special Committee but would remain on the board. The Chapter 11 announcement describes that later change in leadership and the bankruptcy filing.
Rank #2
- REVIEW IMPORTANT TEST INFO: There is a lot to consider with genetic testing. Before purchasing, review important information about Genetic Health Risk*, Carrier Status*, and Pharmacogenetics** reports at 23andme. org/test-info and 23andme. org/test-info/pharmacogenetics. A portion of your purchase may be eligible for FSA/HSA reimbursement***.
- UNDERSTAND YOUR GENETIC HEALTH: Receive 160+ personalized genetic reports, including 50+ Conditions* and wellness reports. Get insights into heart health, metabolic health, mental health, and more. You choose whether to view certain reports.
- TRACK HEALTH GOALS: Health Tracks(SM) show how everyday choices may shape your health over time. Opt in to the Family Health History Tree to input and track information to share with your healthcare provider.
- PLAN AHEAD WITH 45+ CARRIER STATUS REPORTS*: Find out whether you carry a genetic variant for inherited conditions across categories like blood, lung, and hearing health, information you can bring to family planning conversations with your healthcare provider.
- LEARN HOW YOUR BODY MAY RESPOND: FDA-authorized pharmacogenetics reports show how your DNA may impact the way your body processes certain medications**, including some used in heart health and mental health care. Talk to your healthcare provider before making any medication changes.
What happened to 23andMe’s services
After the Chapter 11 process began, TTAM Research Institute acquired 23andMe’s Personal Genome Service and Research Services business lines. TTAM announced on July 14, 2025, that the acquisition was complete and that the services continued operating under TTAM. The completion announcement confirms the transaction’s completion; a planned sale price reported earlier should not be treated as the final transaction value on the basis of that announcement alone.
The 23andMe Research Institute is a separate, later governance context. On October 24, 2025, it announced that Brad Margus and Stephen Quake had joined its board. That institute board is not the same board as 23andMe’s seven independent directors who resigned in 2024. The Institute’s announcement describes those appointments.
Quick Recap
Best Value
- TOP-SELLING CONSUMER DNA TEST: From your origins in over 3,600 places around the world to the most connections to living relatives, no other DNA test kit delivers an experience as unique and interactive as AncestryDNA.
- YOUR DATA, YOUR CONTROL: We give you full control over your genetic information. You decide what to share, and with whom.
- A FEW SIMPLE STEPS: Simply activate your DNA kit online and return your saliva sample in the prepaid package to our state-of-the-art lab. Your results will be available online in roughly six weeks.
- ORIGINS AND INHERITANCE: AncestryDNA provides more precise ancestral origins with greater geographic detail. Our innovative SideView technology takes your results even further by showing your origins and matches by parental side. *Some DNA features require an Ancestry subscription.
- BUILD YOUR FAMILY TREE: Combine what you learn from your DNA results with an Ancestry subscription and gain access to millions of family trees and the world's largest collection of online family history records. *Access to record collections varies depending on subscription level.
Rank #4
- Discover your ancestry and find relatives you never knew existed on both your maternal and paternal sides.
- Get a detailed ethnicity breakdown with the most comprehensive list of ethnicities in the industry: 42 regions, including 7 East Asian regions.
- Simple DNA test kit with a cheek swab - takes only 2 minutes to complete.
- Huge global database enables you to get worldwide DNA Matches.
- Affordable price - includes access to test results. Uses the highest technological standards.
Rank #3
- REVIEW IMPORTANT TEST INFO: There is a lot to consider with genetic testing. Before purchasing, review important information about Genetic Health Risk* and Carrier Status* reports at 23andme. org/test-info. A portion of your purchase may be eligible for FSA/HSA reimbursement***.
- UNDERSTAND YOUR GENETIC HEALTH: Get 10+ Condition reports* that show whether you have genetic variants associated with a higher risk of certain conditions. Includes FDA-authorized reports, and you choose whether to view certain reports.
- PLAN AHEAD WITH 45+ CARRIER STATUS REPORTS*: Discover if you carry a genetic variant for inherited conditions across categories like blood, lung, and hearing health, information you can bring to family planning conversations with your healthcare provider.
- OPTIMIZE YOUR DAILY WELLNESS: See how your genes may influence lifestyle factors like deep sleep, lactose intolerance, genetic weight, and muscle composition.
- MAP YOUR ORIGINS ACROSS 5,000+ REGIONS: Explore your Ancestry Composition, trace maternal and paternal haplogroups (paternal requires a Y chromosome), and dig into your Neanderthal Ancestry. Opt in to find up to 1,500 DNA Relatives, and your Family Tree builds itself automatically.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
